Employees: 231
Size Capricor Therapeutics (CAPR) is a United States Health Care company (Pharmaceuticals: Major) with a market value of $467M, the 2722nd largest of 3,085 United States companies the cockpit tracks. Shares closed at $8.03 on 18 Nov 2026.
Performance Over six months the shares fell 70.2%, against -8.2% for the median peer and -2.2% for the United States market (cap-weighted) — lowest of 20 in its peer set.
Growth Revenue fell 100.0% over the last twelve months (peer median +13.0%).
Capital Return on invested capital runs 124.7 points below its cost of capital (8.5% WACC).
Short interest Short interest is 32.3% of the free float (30 Oct 2026).
Next results Next results expected around 11 Mar 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | $0 | $0 | $22.3M | $25.2M | $2.55M |
| Revenue growth | — | -100% | -12% | +887% | — |
| Gross profit | -$2.56M | -$1.89M | $20.8M | $24.1M | $1.86M |
| EBITDA | -$151M | -$106M | -$41.1M | -$23.0M | -$29.0M |
| Net income | -$148M | -$105M | -$40.5M | -$22.3M | -$29.0M |
| Free cash flow | -$146M | -$81.5M | -$41.5M | -$27.6M | $1.56M |
| Capital expenditure | $26.3M | $11.7M | $1.54M | $2.05M | $3.36M |
| Total debt | $92.2M | $17.9M | $4.83M | $5.61M | $5.94M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | CAPR | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | +21.5% | -3.2% | 3rd highest of 21 |
| 6-month return | -70.2% | -8.2% | lowest of 20 |
| Distance from 52-week high | -80.1% | -36.0% | lowest of 21 |
| Revenue growth (TTM) | -100.0% | +13.0% | lowest of 20 |
| ROIC minus cost of capital | -124.7 pp | -3.3 pp | lowest of 17 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Capricor Therapeutics CAPR | United States | $467M | -70% | -100% | n/a | n/a | n/a | n/a |
| Kwality Pharmaceuticals KPL.NS | India | $467M | +110% | +48% | 22% | 7.2× | n/a | n/a |
| Zhejiang Yatai Pharmaceutical 002370.SZ | China | $468M | -32% | -4% | -11% | 8.8× | n/a | n/a |
| Evolus EOLS | United States | $468M | +7% | +14% | -5% | 1.8× | n/a | n/a |
| Handa Pharmaceuticals 6620.TWO | Taiwan | $469M | +45% | -16% | 30% | 16.6× | 24.8% | +126.7% |
| Hainan Shuangcheng Pharmaceuticals 002693.SZ | China | $465M | -28% | +40% | 13% | 10.8× | 44.1% | +1.0% |
| BlossomHill Therapeutics BLSM | United States | $464M | n/a | n/a | n/a | n/a | n/a | n/a |
| ChengDa PharmaCeuticals 301201.SZ | China | $472M | -47% | +27% | -9% | 4.8× | n/a | n/a |
| YungShin Global 3705.TW | Taiwan | $472M | +5% | -5% | 15% | 2.0× | -3.8% | +0.7% |
| Aquestive Therapeutics AQST | United States | $475M | -9% | +13% | -114% | 10.9× | n/a | n/a |
| Assembly Biosciences ASMB | United States | $458M | -15% | +80% | -32% | 2.2× | n/a | n/a |
| SMS Pharmaceuticals SMSPHARMA.NS | India | $477M | +16% | +13% | 16% | 4.9× | n/a | n/a |
| Shanghai Fudan Forward S&T 600624.SS | China | $478M | 0% | -14% | -34% | 6.4× | n/a | n/a |
| Hansa Biopharma HNSA.ST | Sweden | $479M | +39% | +69% | -190% | 14.9× | -4.7% | +105.3% |
| REGENXBIO RGNX | United States | $480M | +22% | -5% | -120% | 3.1× | n/a | n/a |
| Shanghai MicuRx Pharmaceutical 688373.SS | China | $481M | -8% | +23% | -61% | 19.0× | n/a | n/a |
| Gufic Biosciences GUFICBIO.NS | India | $452M | +48% | +17% | 14% | 4.3× | n/a | n/a |
| Pulike Biological Engineering 603566.SS | China | $449M | -21% | -9% | 5% | 2.4× | 4.5% | +3.3% |
| Hefei Lifeon Pharmaceutical 003020.SZ | China | $486M | -21% | -1% | 10% | 2.0× | n/a | n/a |
| Nanjing Hicin Pharmaceutical 300584.SZ | China | $487M | -29% | +32% | 17% | 4.3× | 3.3% | -1.1% |
| Dong-A Socio 000640.KS | South Korea | $447M | -8% | +11% | 7% | 0.7× | -6.6% | +12.8% |